Vanguard Group
ARQT icon

Vanguard Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Vanguard Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$211M Buy
7,253,936
+107,846
+2% +$2.76M ﹤0.01% 1527
2025
Q3 		$135M Buy
7,146,090
+96,991
+1% +$1.53M ﹤0.01% 1726
2025
Q2 		$98.8M Buy
7,049,099
+231,021
+3% +$3.24M ﹤0.01% 1834
2025
Q1 		$107M Buy
6,818,078
+377,363
+6% +$5.32M ﹤0.01% 1767
2024
Q4 		$89.7M Sell
6,440,715
-521,920
-7% -$5.72M ﹤0.01% 1920
2024
Q3 		$64.8M Buy
6,962,635
+818,345
+13% +$8.08M ﹤0.01% 2070
2024
Q2 		$57.1M Buy
6,144,290
+977,873
+19% +$8.84M ﹤0.01% 2097
2024
Q1 		$51.2M Buy
5,166,417
+269,904
+6% +$2.01M ﹤0.01% 2156
2023
Q4 		$15.8M Buy
4,896,513
+2,017,053
+70% +$5.48M ﹤0.01% 2698
2023
Q3 		$15.3M Buy
2,879,460
+229,072
+9% +$1.95M ﹤0.01% 2662
2023
Q2 		$25.3M Buy
2,650,388
+68,257
+3% +$758K ﹤0.01% 2496
2023
Q1 		$28.4M Buy
2,582,131
+50,719
+2% +$734K ﹤0.01% 2440
2022
Q4 		$37.5M Buy
2,531,412
+278,473
+12% +$4.87M ﹤0.01% 2327
2022
Q3 		$43.1M Buy
2,252,939
+454,276
+25% +$10.3M ﹤0.01% 2257
2022
Q2 		$38.3M Buy
1,798,663
+267,565
+17% +$5.49M ﹤0.01% 2319
2022
Q1 		$29.5M Buy
1,531,098
+16,770
+1% +$284K ﹤0.01% 2570
2021
Q4 		$31.4M Buy
1,514,328
+22,121
+1% +$440K ﹤0.01% 2615
2021
Q3 		$35.6M Sell
1,492,207
-2,069
-0.1% -$47.2K ﹤0.01% 2546
2021
Q2 		$40.8M Sell
1,494,276
-35,294
-2% -$994K ﹤0.01% 2477
2021
Q1 		$44.3M Buy
1,529,570
+442,437
+41% +$13.8M ﹤0.01% 2385
2020
Q4 		$30.6M Buy
1,087,133
+229,967
+27% +$5.63M ﹤0.01% 2436
2020
Q3 		$25.1M Buy
857,166
+479,585
+127% +$12.8M ﹤0.01% 2340
2020
Q2 		$11.4M Buy
377,581
+202,173
+115% +$5.84M ﹤0.01% 2708
2020
Q1 		$5.23M Buy
+175,408
New +$4.71M ﹤0.01% 2954

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group's ARQT Position: Q4 2025 in Review

Vanguard Group increased its Arcutis Biotherapeutics (ARQT) stake by 1.5% in Q4 2025, buying an estimated $2.76M and bringing the position to 7,253,936 shares worth $211M. The position accounts for ﹤0.01% of the portfolio, ranked #1527.

Vanguard Group first reported a position in ARQT in Q1 2020 and has held it in 24 quarters since. 282 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • Vanguard Group held 7,253,936 shares of Arcutis Biotherapeutics worth $211M as of Q4 2025.
  • Vanguard Group bought 107,846 Arcutis Biotherapeutics shares in Q4 2025, an estimated $2.76M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1527 holding.
  • Vanguard Group first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 24 quarters since.
  • 282 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.